Nimotop (Nimodipine)

Nimodipine, the active ingredient in Nimotop, is a calcium channel blocker presented as an intravenous solution for intravenous use. It is employed to prevent cerebral vasospasm after aneurysmal subarachnoid hemorrhage in adult patients. By selectively antagonising L‑type calcium channels in cerebral arteries, it helps maintain adequate cerebral blood flow during the critical post‑hemorrhage period.

GNH USA supplies Nimotop as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Nimodipine is used in the management of cerebrovascular complications associated with subarachnoid hemorrhage.

Aneurysmal subarachnoid hemorrhage: reduces the incidence of delayed cerebral ischemia. Cerebral vasospasm after SAH: promotes arterial dilation to improve cerebral perfusion. Neurological outcome after SAH: contributes to better functional recovery in affected patients.

Nimodipine may be associated with a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Headache - Hypotension - Nausea - Flushing - Dizziness - Tachycardia

Serious or Rare Side Effects: - Severe hypotension leading to syncope - Myocardial infarction or ischemia - Hepatic dysfunction or elevated transaminases - Anaphylactic or severe allergic reactions - Seizures (rare)

When using Nimotop, clinicians should observe several precautionary measures to ensure patient safety.

Blood pressure monitoring: check systolic and diastolic values regularly during infusion. Hepatic function: adjust use in patients with severe liver impairment. Cardiac disease: avoid rapid infusion in patients with unstable angina or recent myocardial infarction. Concomitant vasodilators: use cautiously with other agents that lower blood pressure. Hypersensitivity: discontinue if signs of allergic reaction appear. Store at ambient temperature: keep in original container, protect from moisture and light.

Nimodipine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may markedly increase plasma concentrations. - Concurrent potent vasodilators (e.g., nitroglycerin, hydralazine): risk of severe hypotension. - Other calcium channel blockers (e.g., verapamil, diltiazem): additive cardiovascular effects.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may enhance bradycardia or hypotension. - Diuretics: can potentiate blood pressure lowering. - Macrolide antibiotics (e.g., erythromycin): may modestly increase nimodipine levels.